CTF President Annette Bakker was once again published in FORTUNE, making the case that the repurposing of discontinued (or shelved) drugs for certain indications could have tremendous impact for rare diseases. Arguing that “giving new life to discarded drugs could save patients’ lives,” Dr. Bakker cites examples across disease areas, and also points out the potential for improved ESG (environmental, social governance) scores for pharma/biotech, a metric that is increasingly noticed by investors looking to partner with companies dedicated to improving society. Click here to read the article.
